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[57] ABSTRACT 
This invention relates to cisplatin type fluorescently 
labeled compounds. In particular, the compounds are 
bis (5-aminofluorescein)-dichloroplatinum (II) or cer-
tain substituted analogues thereof. The compounds are 
useful as radiation sensitivity enhancers and as fluores-
cent biological tracers. The invention also relates to a 
unique, single step synthesis for preparing said com-
pounds. 
4 Claims, 3 Drawing Figures 
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LOW TOXICITY RADIATION SENSITIZER 
2 
which is several times less toxic than cisplatin to normal 
living cells. 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application is a division of application Ser. No. 
440,840, filed Nov. 12, 1982 now U.S. Pat. No. 
4,490,543 issued Dec. 25, 1984. 
A further objective of this invention is to provide a 
radiation sensitizer which is at least equal to cisplatin in 
5 radiation sensitization effect, but which is estimated to 
be up to ten times less toxic to normal cells. 
Another object is to provide a compound which like 
cisplatin itself has antineoplastic properties. 
BACKGROUND OF THE INVENTION 10 A still further objective of the present invention is to provide a molecufar tracer which is fluorescent, thus 
providing a unique and highly effective biological 
tracer which is capable of binding to DNA nucleotides, 
proteins, and lipids. 
Yet another objective of this invention is to provide a 
fluorescent biological tracer which also will function as 
an effective biological stain for use in electron micros-
copy and fluorescence microscopy. 
Still another objective of the present invention is to 
provide a radiation sensitizer that has stability and solu-
bility properties which make the compounds easy to 
administer in dosage quantity. 
In addition to being used in cancer chemotherapy, 
cisplatin is also known as a radiation sensitizer. That is, 
such that the cisplatin enhances the effect of ionizing 
radiation on malignant tumors in order to improve local 
and regional cancer treatment by radiation, see, for 15 
example, Overgaard, et al., Cancer Treatment Reports 
Vol. 65, Nos. 5-6, May/June, 1981, p. 501-503, which is 
incorporated herein by reference. There, it is reported 
that cisplatin will enhance the radiation response in 
tumors by a factor of between 1.2 and 1.7 time the effec- 20 
tiveness if no cisplatin is used. The report goes on to 
describe the use of cisplatin as a marked and selective 
enhancement of radiation's effects in solid tumors. Cis-
platin has the formula: 
And another objective of the present invention is to 
provide a radiation sensitizer which is soluble in water 
25 and soluble in common universal solvents such as di-
methylsulfoxide, methyl alcohol, ethyl alcohol, ace-
tone, etc. 
Cl NH3 
" / Pt 
/ " Cl NH3 
The chemical name for cisplatin is cis-diaminedichloro-
platinum(II). It is a square planar molecule and its effec-
tiveness in biological systems is believed to be related to 
Another very important objective of the present in-
vention is to provide a highly effective, single step syn-
30 thesis for production of fluorescently labeled cisplatin 
type compounds, which do not employ cisplatin at all in 
the synthesis procedure, but instead employ readily 
available compounds in a single step, direct combina-
its configuration. The compound was recognized for its 
biological significance in the 1960's and its radiation 35 
sensitizing properties were demonstrated in the mid-
tion synthesis. 
TM method and manner of accomplishing each of the 
above objectives, as well as others, will become appar-
ent from the detailed description of the invention which 
follows hereinafter. 
l 970's. 
SUMMARY OF THE INVENTION 
While cisplatin per se has been known as an effective 
radiation sensitizer, it does have problems which have 
inhibited its practical use. The primary problem is its 40 
high level of toxicity to normal living cells. Thus, while 
it may successfully sensitize a carcinoma, making it This invention relates to cisplatin type fluorescently 
highly susceptible to radiation treatment, it also is quite labeled compounds which are effective radiation sensi-
toxic to the surrounding normal cells. There is, there- tizers. In particular, the compounds are bis(5-amino-
fore, a real and continuing need to develop a radiation 45 fluorescein)dichloroplatinum(II) (abbreviated cis-CFP) 
sensitizer which is at least equally as effective as cispla- or certain substituted analogs thereof. They are equal to 
tin with respect to the enhancement of sensitivity of cisplatin from the standpoint of their radiation sensitiv-
carcinomas to radiation, but which will allow such ity enhancement, but are up to ten times less toxic to 
sensitization without being toxic to surrounding normal normal living cells than cisplatin. In addition, the com-
living cells. 50 pounds are highly effective, fluorescent biological trac-
Needless to say, if one could develop a radiation ers. The invention also relates to a unique, single step 
sensitizer of high level sensitizing effect, but with mini- synthesis for preparing fluorescently labeled cisplatin 
mal toxicity to surrounding normal living cells, the net type compounds, without ever employing cisplatin in 
effect would be that smaller doses of radiation could be the synthesis route. As a result, the synthesis involves a 
used to give the effect now achieved with only larger 55 platinum salt and a relatively non-toxic 5-aminofluore-
radiation doses and thus, the total body exposure to 
radiation reduced. Alternatively, for a given radiation scein, which are readily available. 
dose, its effectiveness could be increased without fear of 
causing high level toxicity to surrounding normal tissue 
cells. 60 
It is a primary objective of the present invention to 
provide a radiation sensitizer which is at least equal to 
cisplatin in selective enhancement of radiation response, 
but which provides such radiation response with a 
much, much lower toxicity level to normal live cells. 65 
An additional objective of the present invention is to 
provide a radiation sensitizer which is at least equal to 
cisplatin in enhancement of radiation response, but 
BRIEF DESCRIPTION OF THE DRAWINGS 
The drawings are graphs illustrating the good radia-
tion sensitizing properties of the compounds of this 
invention, coupled with their low toxicity level com-
pared to cisplatin. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The compounds of this invention have the following 
formula: 
4,569,932 
4 3 
compounds of this invention, it is not believed that there 
has been a biological tracer which is both fluorescent 
and also offers binding properties similar to that of 
cisplatin in that it may bind to nucleic acids, proteins 
5 and lipids, and thus be easily traceable. This fluorescent 
property, coupled with the binding ability to biologi-
cally important compounds, allows for fluorescent la-
beling of cells in biological work. 
10 While the compounds discussed have been referred 
to as platinum compounds, it is possible that other com-
pounds can be made employing as the metal atom, any 
of the metals of the platinum metal series, that is, rubid-
ium, rhodium, palladium, osmium, irridium, and plati-
R'O 
wherein "X" is a halide and Rand R' are selected from 
the group consisting of hydrogen, C1 to C12 alkyl, C1 to 
C12 alkenyl, C1 to C12 alkynyl, and aryl. Preferably "X" 
15 num. It is therefore contemplated as still within the 
scope of this invention if the central metal atom of the 
platinum compounds is replaced with other of the re-
ferred to metals of the platinum metal series. 
is a chloride or bromide, and most preferably chloride. 20 It is preferred that Rand R' be selected from the group 
consisting of C1 to C6 alkyl, alkenyl, alkynyl, and aryl. 
Most preferably, both R and R' are hydrogen. 
The very most preferred compound of the invention 
is bis(5-aminofluorescein)dichloroplatinum(II). 
The compounds of the present invention can be 25 
thought of as fluorescein derivatives of cisplatin. 
Cisplatin has been known for several decades but has 
only become biologically important since about the 
mid-1960's. It is a square planar molecule known to 
have adverse properties to normal, but especially to 30 
neoplastic cells. It is also known as an effective radia-
tion sensitizer. The term "radiation sensitizer" refers to 
enhancement of the effect of ionizing radiation on cells, 
most typically malignant cells in order to improve local 
and regional cancer treatments. Cisplatin selectively 35 
sensitizers and enhances the effective radiation response 
in malignant growths with a lesser effect in normal 
tissues. Thus, cisplatin has been accorded some high 
level interest, because of its potential use in chemother-
·. apy. However, one primary disadvantage with cisplatin 40 
is that it has a high level of toxicity to normal tissue 
cells. 
Surprisingly, and contrary to the expectations in 
working with cisplatin per se, the fluorescein deriva-
tives of this invention are equal to cisplatin as radiation 45 
sensitizers, but, contrary to cisplatin, have a very low 
level toxicity to surrounding tissue cells. In fact, data 
developed to date, reveal a toxicity level up to as much 
as ten times lower than cispiatin. As a result, the com-
pounds of this invention, and particularly the most pre- 50 
ferred compound bis(5-aminofluorescein)dichloro-
platinum(II), can be used as a much more effective 
radiation sensitizer than cisplatin. In particular, since 
the aminofluorescein derivative has a low toxicity level, 
larger quantities can be used in dosage treatments. As a 55 
result, successful radiation treatments can occur with 
much smaller radiation doses, resulting in overall re-
duced body exposure to radiation. Then too, large doses 
of the radiation sensitizer can be used, increasing the 
radiation sensitization effect, without any significant 60 
worry of the high level toxicity to normal cells. In 
particular, toxicity levels of the most preferred com-
pound of this invention are up to ten times less than 
cisplatin. 
The compounds of the present invention are also 65 
useful as biological tracers, since they are both fluores-
cent and have high binding capabilities to nucleic acids, 
proteins and lipids. Prior to the development of the 
Another highly important feature and advantage of 
the compounds of the present invention is that they 
have stability and solubility characteristics which make 
them easy to work with from the standpoint of dosage 
units. That is to say, they are soluble in water, they are 
relatively stable, and they will dissolve in many univer-
sally employed solvents such as dimethylsulfoxide, 
methanol, ethanol and acetone. 
A surprisingly simple and straightforward single step 
reaction synthesis has been developed for producing the 
compounds of this invention. The method is surprising 
because one would normally except cisplatin per se to 
be the starting material, since the compounds are deriv-
atives of cisplatin. However, cisplatin is not involved in 
the reaction at all. And yet, the compound which is 
produced has all of the r~diation sensitivity properties 
of cisplatin. In accordance with the process of this in-
vention, 5-aminofluorescein (Isomer I), or a substituted 
5-aminofluorescein, is reacted with an alkali metal tetra-
chloroplatinate(II) in a single step, direct combination 
synthesis. 5-aminofluorescein (Isomer I) has the for-
mula: 
HO 
The alkali metal tetrachloroplatinate(II) is preferably 
potassium tetrachloroplatinate(II) of the formula 
K1[PtCl4]. In the preferred methodology, an aqueous 
solution of potassium tetrachloroplatinate(II) is mixed 
with a hot methanol solution of 5-aminofluorescein, 
with the molar ratio of potassium tetrachloro-
platinate(II) to 5-aminofluorescein being 1:2. The solu-
tions are mixed and the mixture is heated (with evapora-
tion) at a slightly elevated temperature, perhaps 60° C. 
After cooling to room temperature, a brown precipitate 
forms which can be separated and recrystallized. 
The following examples are offered to further illus-
trate, but not limit, the invention. It is understood that 
modifications may be made in the illustrated examples. 
4,569,932 
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EXAMPLES 
Preparation of bis(5-aminofluorescein)dichloro-
platinum(II) was accomplished using direct combina-
tion of an aqueous solution of potassium tetrachloro- 5 
platinate(II) and 5-aminofluorescein. In particular 0.415 
grams of K1[PtCl4] in 25 milliliters of water was added Cisplatin 
cis-CFP 
6 
TABLE 1 
Concentration of 
Compound 
IOOuM 
IOOuM 
Toxicity after 
~ hour at room 
temperature 
[no radiation 
survival] 
10% 
100% survival 
Radiation 
Enhancement 
Ratio 
2.4 
1.6 
Even though the enhancement of the 100 uM concen-
tration is less for cis-CFP than for displatin, the extreme 
differences in toxicity demonstrate the utility of cis-
CFP as compared to cisplatin. 
to 0.694 grams of 5-aminofluorescein in 50 milliliters of 
boiling methanol. They were mixed, and the solution 
was kept at about 60° C. for one hour. Thereafter, it was JO 
allowed to cool, at which point a brown precipitate was 
observed. The precipitating compound was filtered, 
washing a little with absolute ethanol, and then with 
diethyl ether. The brown compound remained. It 
weighed 0.4 grams. 15 Though difficult to compare directly, other work 
using mice to study cisplatin-induced radiosensitization 
shows a radiation enhancement ratio of up to 1. 7. This 
is comparable to the 1.6 value demonstrated for cis-CFP 
in the bacterial system. 
The reaction process was run again, exactly as de-
scribed above, and gave a brown solid of 0.5 grams. 
Nuclear magnetics resonance (NMR) testing, infra-
red (IR) analysis, visible-UV spectroscopy, and quanti-
tative, elemental analysis all confirmed the presence of 20 
bis(5-aminofluorescein)dichloroplatinum(II). In these 
runs, the starting platinum compound came from the 
Alpha Division of Ventron Corporation, and the start-
ing 5-aminofluorescein compound came from Sigma 
Chemical in St. Louis, Mo. Of course, other convenient 25 
and suitable sources for the starting materials may be 
utilized. 
Numerous repetitions of the synthesis procedure 
shown here, have occurred and all upon various analy-
sis techniques mentioned herein confirm the presence of 30 
bis 5-aminofluorescein)dichloroplatinum(II). 
The process was repeated using as the starting mate-
rial K1[PtBr4] and the resulting product was bis(5-
aminofluorescein)dibromoplatinum(II). 
The bis(5-aminofluorescein)dichloroplatinum(II) pre- 35 
pared in the manner previously described herein, was 
tested for effectiveness as a radiation sensitizer. In par-
ticular, the compound was complexed with nucleotides 
in vitro. The stability of the compound was studied in a 
buffered saline solution over a period of time. Finally, 40 
the cell growth effects of the compound from the stand-
point of its effects on living cells were studied, as de-
scribed below. 
The drawings illustrate the effective nature of the 
compounds of this invention as radiation sensitizers, and 45 
compare the toxicity level of the compounds of this 
invention with the toxicity level of cisplatin from the 
standpoint of their effects on living cells. 
FIG. 1 shows the effectiveness of the compound of 
this invention, in particular bis(5-aminofluorescein)di- 50 
chloroplatinum(II) in terms of its effectiveness as a 
radiation sensitizer. In particular, in looking at FIG. 1, 
the "x" axis shows radiation dose as measured in kilo-
rads (krad). The "y" axis shows the surviving fraction 
of bacterial cells (S. typhimurium Tm 677). The line 55 
represented by black dots and dashes shows the effect of 
radiation alone on this bacterial system under a nitrogen 
blanket. This simulates anaerobic conditions in vivo. 
The lines showing squares with dashes and pulses with 
dashes shows the decrease in survival produced by 20 60 
um and 100 um cis-CFP respectively over a range of 
radiation dosages. The radiosensitization produced by 
cis-CFP exhibits a dose dependent effect. It also exhibits 
a much reduced toxicity as compared to equamolar 
concentrations of cisplatin; this makes it difficult to 65 
make direct comparisons. Studies using the S. typhimu-
rium Tm 677 bacterial system produce the following 
data. 
Also, cisplatin under nitrogen is an assay using E. coli 
exposed to 5 X IQ-5M cisplatin shows an enhancement 
ratio of about 1.77. It therefore can be seen that al-
though direct comparision is difficult, they are compa-
rable in radiation sensitizing ability. 
FIG. 2 shows the growth of a culture of Tetrahy-
mena in a nutrient medium which comprises 2% by 
weight of proteose peptone, 0.1 % by weight sodium 
hydrogen phosphate, 0.1 % sodium acetate and with the 
balance being distilled water. The "x" axis shows cul-
ture growth in time with the "y" axis indicating media 
density, an indication of cell numbers. As can be seen, 
the greatest cell growth is exhibited in the control, 
which are free living and growing protozoan cells in the 
presence of a nutrient. The toxicity of cisplatin when 
added to the control solution at a concentration of IQ-5 
molar is also shown. The toxicity of the compounds of 
this invention at IQ-4 molar and IQ-5 molar concentra-
tions are likewise shown. It can be seen that the level of 
toxicity compounds of the present invention is much, 
much less at a given molar concentration than is cispla-
tin. This is further illustrated in FIG. 3, which shows 
the same free living protozoan cell Tetrahymena, but 
shows the motility rate declining in the presence of 
cisplatin and a compound of the invention. Cisplatin is 
the dotted line and the compound of the invention is the 
solid line. There, the "x" axis measures time of exposure 
with the "y" axis measuring the motility rate of the 
organisms. The steeper the line indicating the mobility 
of the organism, the more toxic the compound. There, 
the concentration in both instances of cisplatin and the 
compound of the invention was 2 X IQ-3 molar. It can 
be seen that at any given time, the mobility is much 
more reduced by cisplatin than the compound of this 
invention, indicating a much higher toxicity level of 
cisplatin. 
It therefore can be seen that the compounds of the 
present invention are substantially equal in radiation 
sensitizing effect to cisplatin, but that they are up to as 
many as ten times less toxic to normal living cells, see 
FIGS. 2 and 3 and the data presented therein. 
Thus, the invention accomplishes at least all of its 
stated objectives. 
What is claimed is: 
1. A method of increasing the radiation sensitivity of 
living cells comprising: 
administering to an animal a small radiation sensitiz-
ing effective amount of a compound of the formula 
7 
4,569,932 
5 
10 
HO 
where Xis a halide. 15 2. The method of claim 1 wherein Xis chloride. 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
3. The method of claim 1 wherein X is bromide. 
4. The method of claim 1 wherein the amount of said 
compound administered is from about 20 micromoles to 
about 100 micromoles. 
* * * * 
